Entrada Therapeutics (TRDA) Return on Sales [ROS] (2023 - 2026)
Entrada Therapeutics' Return on Sales [ROS] was -5007.02% in Q2 2026, down 2604.50 percentage points from -2402.51% a year earlier and down 172.39 percentage points from the prior quarter.
Entrada Therapeutics (TRDA) Return on Sales [ROS] (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Entrada Therapeutics' Return on Sales [ROS] was -3767.07% through Jun 30, 2026, down 3646.07 percentage points year-over-year; for FY2025, it was -621.13%, down 643.44 percentage points from FY2024.
- In earlier years, Return on Sales [ROS] was 22.30% in FY2024 (+24.75 pp) and -2.45% in FY2023.
- The Q2 2026 figure marks the lowest quarterly Return on Sales [ROS] in data going back to Q1 2023.
- Compared with a year earlier, Return on Sales [ROS] has declined for eight straight quarters, with an average year-over-year change of -2017.75 percentage points over the last eight quarters.
- The best year-over-year quarter for Return on Sales [ROS] over five years was Q2 2024 (a gain of 146.12 percentage points); the worst was Q1 2026 (a drop of 4728.64 percentage points).
- Per Business Quant data, TRDA's Return on Sales [ROS] in the three quarters before Q2 2026 was -4834.63% (Q1 2026), -3249.27% (Q4 2025) and -2915.18% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 28.37% |
| 10 | Entrada Therapeutics | 221.16 Mn | 221.16 Mn | - | -5,007.02% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,007.02% |
| Mar 31, 2026 | -4,834.63% |
| Dec 31, 2025 | -3,249.27% |
| Sep 30, 2025 | -2,915.18% |
| Jun 30, 2025 | -2,402.51% |
| Mar 31, 2025 | -105.99% |
| Dec 31, 2024 | -15.69% |
| Sep 30, 2024 | -110.67% |
| Jun 30, 2024 | 56.42% |
| Mar 31, 2024 | 35.71% |
| Dec 31, 2023 | 11.72% |
| Sep 30, 2023 | 32.04% |
| Jun 30, 2023 | -89.70% |
| Mar 31, 2023 | -22.88% |
Entrada Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=TRDA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "TRDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=TRDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();